Gastro-Intestinal (GI) drugs market is a potentially huge market with many different indications, drug types and treatment regimens.

Transparency Market Research and PRNewswire reports predict the global GI drugs market to grow with a CAGR between 4.5 % and 5.0 % from 2017 to 2023. While, it was worth USD 46.5 Billion in 2016, it is estimated to reach US$61.6 bn by the end of 2024, expanding at a CAGR of 4.90%.

No wonder, it’s gaining a lot of interest by drug developers. Interest in GI field is backed by strong market potential.


Regions for GI Clinical Trials

  • A quick look at the Clinicaltrials.gov provides interesting figures. A total of 27,022 clinical trials have been recorded in gastrointestinal disorders around the world, with most of them in North America (10,510), particularly United states (9,615); Europe (7,916) and East Asia (5,501).
  • Currently, ongoing studies on GI Disorders are 6,434, with North America (2,726), Europe (2,030) and East asia (1,747), taking the biggest pie.
  • Having considered this, it’s also clear that potential of each region may vary with type of GI indications being explored in clinical trial.

Regions for Duodenal Ulcer and Dyspepsia Clinical Trials

While, GI trials include many different therapeutic indications, like ulcers, crohn’s disease, IBD etc., duodenal ulcer and dyspepsia are some of the significantly interesting field for drug developers. Globally, a total of 108 studies are going on in duodenal ulcer mostly in East Asia (66), Japan (30), Europe (11) and North America (13).

In a recently performed assessment on Credevo, feasibility of a clinical trial on Sucralfate was explored in duodenal ulcer and dyspepsia. Objective was to select the best regions for site identification and further site selection.

Out of total 8 countries targeted, 3 countries stood out as the clear winners. These were Poland, Romania and South Korea.

Poland, Romania and South Korea

Feasibility of clinical trial on duodenal ulcer and dyspepsia showed that these 3 countries could be very good site for GI clinical trials.

Let’s look at the details of this feasibility and understand more about these regions.

Target Regions for Feasibility

A group of countries from Europe, South Asia, South-East Asia and East Asia were chosen based on sponsor’s previous experience, viability and expected recruitment potential. These countries included

  1. India,
  2. Indonesia,
  3. Korea (south),
  4. Philippines,
  5. Thailand,
  6. Vietnam,
  7. Poland, and
  8. Romania

Clinical Trial Design for Feasibility

The study was designed as a Randomized, Double Masked, Parallel Group, Placebo Controlled, Multicentric Study to evaluate the Efficacy and Safety of Sucralfate Suspension (1g/10 mL) in Subjects with Dyspepsia Symptoms and Endoscopically Confirmed Active Duodenal Ulcer.

This preliminary trial design was based on earlier OGD (USFDA) recommendation for conducting clinical trial for Sucralfate. Currently, this recommendation has been changed to exclude any clinical trial required.

Here are the two versions of OGD (USFDA) recommendations for Sucralfate submission.

The trial design included patients in duodenal ulcer and dyspepsia. Here are the main inclusion criteria considered.

  1. Ability to provide informed consent
  2. Male or females aged ≥ 18 and ≤ 65 years
  3. Subjects with dyspepsia symptoms along with one or two active duodenal ulcer of at least 3 mm in diameter and not exceeding 25 mm in diameter as determined by upper GI endoscopy.
  4. Subjects who are negative for H.pylori at baseline or subject continues to have the presence of an ulcer after appropriate treatment and eradication of H.pylori.
  5. Subjects who are willing to refrain from use of any other ulcer treatment during the 8-week treatment period, other than the study treatment, provided antacid and acetaminophen.
  6. Subjects had no clinically significant findings on physical examination, ECG, clinical laboratory tests and urine analysis at the discretion of Principal Investigator.

A detailed study design can be accessed on Credevo

Duodenal Ulcer and Dyspepsia

  • Duodenal ulcer, an ulcer in the first part of the intestine (duodenum), is most likely caused by an alteration in balance between the acid produced in stomach and natural mucus barrier protecting the lining of duodenum.
  • The most common symptoms of a duodenal ulcer are upper abdominal pain that may improve with eating.  Other symptoms include belching, vomiting, weight loss, or poor appetite.
  • Dyspepsia is a condition of impaired digestion, described by a group of symptoms, which may include pain, discomfort, bloating, feeling uncomfortably full after eating, nausea, loss of appetite, heartburn, burping up food or liquid (regurgitation), burping. In some cases dyspepsia may be the first symptom of duodenal ulcer disease.  

Feasibility Responses and Assessments Results

Results from this feasibility assessment threw interesting insights.

  1. Investigators in Poland, Romania and South Korea were most responsive.
  2. More than 100% of required responses were received.
  3. Average prospective recruitment rate was 3.44 patients per site per month.
  4. South Korean investigators reported highest prospective recruitment rate of 5 patients per site per month, followed by investigators from Romania (4) and Poland (2.44).
  5. Highest individual prospective recruitment rate was 10 patients/site/month and the lowest was 1 patient/site/2 months.

These figures could be very helpful in planning studies in these regions.

Study Plan Based on Feasibility Results

Consider a scenario, where referred study is going to be planned (although, it’s not recommended, as USFDA does not require this clinical trial for Sucralfate anymore) in these 3 countries. Besides the patient recruitment and treatment period, regulatory timelines will also play a major role in projecting the study duration.

Let’s assess study timelines for this project with following assumptions.

  • Total patients to be recruited: 595
  • Treatment period: 2 months
  • Number of sites required: 15 with South Korea, Romania, and Poland having 5 sites each.
  • Competitive recruitment among sites.

Regulatory Approvals

With a reasonable time-frame of 30 days for RA and IRB approval done in parallel, South Korea offers very favorable time scenario (see more details on South Korea – Clinical Trials Regulatory Process).

This also gives South Korea, one extra month compared to Poland and Romania – both have 60 days as regulatory approval timelines. See regulatory process details on Poland and Romania.


Within approximately 10 months of recruitment, all 15 sites will be able to complete the target.

Total Project Timeline

Considering above scenario, here is a most likely prospective project schedule

 Process Date
Study Start (Assumption) 1-Jan-2018
Regulatory Submission Starts 16-Jan-2018
First Regulatory Approval 15-Feb-2018
First Patient Recruitment 2-Mar-2018
Last Patient Recruitment 26-Jan-2019
Last Patient Last Visit 27-Mar-2019


Of course, with change in basic assumptions, these timelines can be changed. But, the important aspect remains the quality investigators, who can provide a great recruitment rate.

Contact us, if you’d like to connect with these investigators from South Korea, Romania and Poland


  1. https://patient.info/health/duodenal-ulcer
  2. https://www.medicinenet.com/dyspepsia/article.htm
  3. https://www.mayoclinic.org/diseases-conditions/peptic-ulcer/diagnosis-treatment/drc-20354229
  4. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0fb67b1c-b4c0-46f2-8a81-df1510e006aa
  5. https://en.wikipedia.org/wiki/Sucralfate
  6. https://www.prnewswire.com/news-releases/gastrointestinal-drugs-market-global-industry-analysis-trends-market-size–forecasts-to-2023-300528037.html
  7. https://www.transparencymarketresearch.com/gastrointestinal-drugs-market.html
  8. https://www.marketresearchfuture.com/reports/peptic-ulcer-drugs-market-2445
  9. http://www.wikinvest.com/stock/ViroPharma_(VPHM)/Fda_Guidance_Bioequivalence_Requirements_Locally-acting_Drugs_Fully_Supports
  10. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM573202.pdf